AgomAb Therapeutics NV

L’ultimo trimestre disponibile per AgomAb Therapeutics NV

Dal 6-K dell’azienda.

Cosa ha detto il management

“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,”

Citato alla lettera dal comunicato, e mostrato solo quando il documento lo attribuisce a una persona con nome e cognome.

Cosa fa AgomAb Therapeutics NV

Crohn’s Disease Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

La descrizione dell’azienda stessa, come compare in calce al comunicato.